Aignostics develops AI-driven solutions for precision medicine, turning complex biomedical and pathology data into actionable insights for drug development and improved patient outcomes. Founded as a spin-off from Charité Berlin, the company operates from offices in Berlin and New York and partners with leading academic and industry organizations.

Our mission is to transform drug development and improve patient outcomes by applying advanced machine learning and multimodal data integration to discover targets, biomarkers, and clinically useful diagnostic tools.

We offer pathology foundation models and the Atlas product series, including Atlas H&E-TME for tumor microenvironment profiling. Services include Target & Biomarker Discovery, Translational Research, and Digital Diagnostics to support work from early discovery through regulated clinical applications.

Aignostics has proprietary access to multimodal data and pathology samples representing over 30 million patients from leading hospitals and laboratories. The company holds ISO 13485 and ISO 27001 certifications and maintains a GCP-ready clinical trial platform.

The team includes data scientists, machine learning engineers, pathologists, and biologists. Aignostics has co-developed foundation models with partners such as Mayo Clinic and collaborates with industry partners (e.g., Bayer) on multimodal Target ID platforms and validation studies.

Open positions and hiring information: https://aignostics.com/company/careers#listing. General contact and inquiries: https://aignostics.com/contact. For company updates and research highlights, see the company LinkedIn page: https://www.linkedin.com/company/aignostics